Skip to main content

Table 3 Patient characteristics

From: Association between hydroxocobalamin administration and acute kidney injury after smoke inhalation: a multicenter retrospective study

CharacteristicsAll patients, N = 739Survivors, N = 496Non-survivors, N = 243p
At admission
 - Age in years50 (36–63)46 (33–59)56 (43–72)< 0.0001
 - Sex female, n (%)271 (36.7)180 (36.3)91 (37.4)0.8214
 - BMI in kg/m225 (22–28)24 (22–28)25 (22–29)0.0822
 - Prehospital cardiac arrest (%)46 (6.2)11 (2.2)35 (14.4)< 0.0001
 - Prehospital GSC /1515 (9–15)15 (13–15)14 (3–15)< 0.0001
Comorbidities
 - CKD, n (%)6 (0.8)2 (0.4)4 (1.6)0.0948
 - Hypertension, n (%)141 (19.1)81 (16.3)60 (24.7)0.0088
 - Diabetes mellitus, n (%)54 (7.3)28 (5.6)26 (10.7)0.0198
 - CAOD, n (%)22 (3)7 (1.4)15 (6.2)0.0008
 - CHF, n (%)33 (4.5)20 (4)13 (5.3)0.4858
Burn characteristic
 - Burn, n (%)577 (78.1)357 (72)220 (90.5)< 0.0001
 - TBSA %20 (3–47)12 (0–30)50 (20–73)< 0.0001
 - 3rd degree TBSA %9 (0–30)2 (0–15)33 (10–58)< 0.0001
SOFA at admission4 (1–7)2 (1–5)7 (3–10)< 0.0001
MAP in mmHg86 (72–101)89 (76–102)80 (62–97)< 0.0001
Vasopressor, n (%)226 (30.6)90 (18.1)136 (56)< 0.0001
Hydroxocobalamin, n (%)386 (52.2)239 (48.2)147 (60.5)0.0021
HbCO %4 (2–10)4 (2–11)3 (2–7)0.0323
Biological data
 - Plasmatic lactate in mmol/L3.0 (1.8–5.2)2.5 (1.4–3.8)4.8 (3–7.6)< 0.0001
 - Serum creatinine in μmol/L76 (59–101)71 (56–88)100 (72–123)< 0.0001
 - Maximal serum creatinine in μmol/L100 (73–162)84 (68–113)137 (102–212)< 0.0001
Inhalation fibroscopic status (%)305 (41.3)175 (35.3)130 (53.5)< 0.0001
 - Grade 0, n1 (0.1)1 (0.2)0 (0)1
 - Grade 1, n121 (16.4)90 (18.2)31 (12.8)0.0795
 - Grade 2, n110 (14.9)67 (13.5)43 (17.7)0.1638
 - Grade 3, n73 (9.9)17 (3.4)56 (23.1)< 0.0001
 - During ICU hospitalization
 - AKI in the first week, n (%)288 (39)126 (25.4)162 (66.7)< 0.0001
  - Stage of AKI day 7
  - Stage 1, n (%)102 (13.8)63 (12.7)39 (16)0.2601
  - Stage 2, n (%)39 (5.3)16 (3.2)23 (9.5)0.0007
  - Stage 3, n (%)147 (19.9)47 (9.5)100 (41.2)< 0.0001
  - Severe AKI186 (25.2)63 (12.7)123 (50.6)< 0.0001
 - RRT at day 7, n (%)136 (18.8)44 (8.9)92 (37.9)< 0.0001
 - RRT in ICU, n (%)183 (24.8)58 (11.7)125 (51.4)< 0.0001
 - MAKE, n (%)313 (42.4)69 (13.9)243 (100)< 0.0001
 - Shock in ICU, n (%)402 (54.4)191 (38.5)211 (86.8)< 0.0001
 - Length of stay in ICU15 (3–44)25 (4–50)6 (1–24)0.0001
 - SAPS242 (27–60)32 (22–46)61 (46–75)< 0.0001
Nephrotoxic in ICU
 - Aminoglycoside188 (25.4)115 (23.2)73 (42.9)0.0548
 - Vancomycin41 (5.5)22 (4.4)19 (7.8)0.4011
 - Contrast product74 (10)41 (8.3)33 (13.6)0.0331
  1. All data are expressed as median ± 25–75 interquartile or percentage (%)
  2. BMI body mass index, GCS Glasgow coma scale, CKD chronic kidney disease, CAOD chronic arterial occlusive disease, CHF chronic heart failure, TBSA total body surface area, SOFA sequential organ failure assessment, MAP mean arterial pressure, HbCO carboxy hemoglobin, ICU intensive care unit, AKI acute kidney injury, RRT renal replacement therapy, MAKE major associated kidney events, SAPS2 simplified acute physiology score 2